These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 23049357)
21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]. Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090 [No Abstract] [Full Text] [Related]
23. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540 [TBL] [Abstract][Full Text] [Related]
24. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356 [TBL] [Abstract][Full Text] [Related]
25. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
26. [Mutation Rate and Clinical Characteristics of CALR, JAK2 V617F and MPL W515K Genes in Patients With Primary Thrombocythemia]. Yu XW; Huang DH; Guo JX; Huang YQ; Xie RT; Cai JF Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):866-870. PubMed ID: 29950234 [TBL] [Abstract][Full Text] [Related]
27. MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms. Akpınar TS; Hançer VS; Nalçacı M; Diz-Küçükkaya R Turk J Haematol; 2013 Mar; 30(1):8-12. PubMed ID: 24385746 [TBL] [Abstract][Full Text] [Related]
29. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196 [TBL] [Abstract][Full Text] [Related]
30. A phase 1 study of the Janus kinase 2 (JAK2) Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680 [TBL] [Abstract][Full Text] [Related]
31. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Boyd EM; Bench AJ; Goday-Fernández A; Anand S; Vaghela KJ; Beer P; Scott MA; Bareford D; Green AR; Huntly B; Erber WN Br J Haematol; 2010 Apr; 149(2):250-7. PubMed ID: 20151976 [TBL] [Abstract][Full Text] [Related]
32. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766 [TBL] [Abstract][Full Text] [Related]
33. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Beer PA; Campbell PJ; Scott LM; Bench AJ; Erber WN; Bareford D; Wilkins BS; Reilly JT; Hasselbalch HC; Bowman R; Wheatley K; Buck G; Harrison CN; Green AR Blood; 2008 Jul; 112(1):141-9. PubMed ID: 18451306 [TBL] [Abstract][Full Text] [Related]
34. Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575 [TBL] [Abstract][Full Text] [Related]
35. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT. Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847 [TBL] [Abstract][Full Text] [Related]
36. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Zhan H; Spivak JL Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323 [TBL] [Abstract][Full Text] [Related]
37. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906 [TBL] [Abstract][Full Text] [Related]
38. JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East. Safavi M; Monabati A; Safaei A; Mirtalebi MS; Faghih M Iran J Pathol; 2021; 16(2):190-194. PubMed ID: 33936230 [TBL] [Abstract][Full Text] [Related]
39. [CALR gene mutation detection and clinical observation of 150 essential thrombocythemia patients]. Zhang X; Zhou M; Chao H; Lu X; Cen L Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):378-82. PubMed ID: 26031522 [TBL] [Abstract][Full Text] [Related]